Novartis has broken ground on construction of the first cell culture-derived influenza vaccines manufacturing plant in the United States. Once completed, the Holly Springs, North Carolina facility is expected to annually produce up to 50 million doses of seasonal trivalent flu vaccines or up to 150 million monovalent doses within six months of a pandemic declaration.
Completion of the facility is expected in late 2009, and following validation and FDA approval, initial vaccine production at the site is anticipated for 2011.
An investment of approximately $600 million, which includes a $220 million grant from the US Department of Health and Human Services is planned to complete the Holly Springs facility. In addition to the significant investment in plant construction and equipment, the site will bring more than 350 new job opportunities to the area, including entry level, technicians, supervisors and management.